申请人:Cheng Leifeng
公开号:US20090023704A1
公开(公告)日:2009-01-22
The present invention relates to novel xanthine compounds of the general formula (I)
wherein R
1
, R
2
, R
3
and R
4
are as defined,
having a positive allosteric GABA
B
receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABA
B
agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).
本发明涉及一种新型黄嘌呤化合物,其通式为(I),其中R1,R2,R3和R4如定义所述,具有正向变构GABAB受体(GBR)调节剂效应,以及制备所述化合物的方法和它们的用途,可选与GABAB激动剂结合,用于抑制短暂性下食管括约肌松弛,治疗胃食管反流病,以及用于治疗功能性胃肠疾病和肠易激综合征(IBS)。